Cargando…

92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship

BACKGROUND: Patients who develop prosthetic joint infections (PJI) may be prescribed chronic antibiotic suppression (CAS) ( > 6 months of antibiotics) after initial antibiotic treatment for the PJI. Patients at low risk of recurrent infection may be good targets for antibiotic stewardship. De-imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Dukes, Kimberly, Walhof, Julia, Sekar, Poorani, Nair, Rajeshwari, Suzuki, Hiroyuki, Suh, Daniel, Sherlock, Stacey Hockett, Alexander, Bruce, Richardson, Kelly, Beck, Brice, Reisinger, Heather Schacht, Pugely, Andrew, Puig-Asensio, Mireia, Schweizer, Marin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644068/
http://dx.doi.org/10.1093/ofid/ofab466.294
_version_ 1784610000389275648
author Dukes, Kimberly
Walhof, Julia
Sekar, Poorani
Nair, Rajeshwari
Suzuki, Hiroyuki
Suh, Daniel
Sherlock, Stacey Hockett
Alexander, Bruce
Richardson, Kelly
Beck, Brice
Reisinger, Heather Schacht
Pugely, Andrew
Puig-Asensio, Mireia
Schweizer, Marin
author_facet Dukes, Kimberly
Walhof, Julia
Sekar, Poorani
Nair, Rajeshwari
Suzuki, Hiroyuki
Suh, Daniel
Sherlock, Stacey Hockett
Alexander, Bruce
Richardson, Kelly
Beck, Brice
Reisinger, Heather Schacht
Pugely, Andrew
Puig-Asensio, Mireia
Schweizer, Marin
author_sort Dukes, Kimberly
collection PubMed
description BACKGROUND: Patients who develop prosthetic joint infections (PJI) may be prescribed chronic antibiotic suppression (CAS) ( > 6 months of antibiotics) after initial antibiotic treatment for the PJI. Patients at low risk of recurrent infection may be good targets for antibiotic stewardship. De-implementation of CAS could potentially reduce the emergence of antibiotic resistant organisms and decrease antibiotic-associated adverse events. Our ongoing study aims to characterize clinical decision-making processes about CAS prescribing and identify points for antibiotic stewardship interventions to stop CAS prescribing for patients who will not benefit. METHODS: We conducted semi-structured interviews with 33 physicians and nurses at 8 Veterans Affairs hospitals, chosen for variation in hospital size, complexity, region, and CAS prescribing. Interviewees included orthopedic surgeons, infectious disease (ID) physicians, hospital epidemiologists, nurses, nurse managers, and primary care physicians (PCPs). We conducted inductive, consensus-based thematic analysis on interview transcripts, using the program MAXQDA. RESULTS: Participants reported a complex decision-making process that included a range of collaborative approaches with other clinicians and patients. Their risk-benefit calculation for CAS usually included the type of revision surgery performed, the evidence base, the organism, and patient factors. Surgeons and ID physicians, the primary CAS prescribers, collaborated variably and sometimes consulted pharmacists or antibiotic stewards. Participants emphasized the importance of clinician autonomy and buy-in to order to effect practice change based on evidence, rather than top-down policies. They identified other significant time points that occurred before or after the CAS prescribing decision (initial PJI treatment decisions, follow-up appointments) and identified other decision makers about CAS maintenance (e.g., patients, PCPs). (See Figure 1). Figure 1. Decision Points Relevant to Prescribing or Maintenance of Chronic Antibiotic Suppression after PJI. PJI, prosthetic joint infection; ID, Infectious Diseases physician; PCP, primary care physician; IV, intravenous [Image: see text] CONCLUSION: Interventions to optimize CAS prescribing should incorporate clinician concerns about prescriber autonomy and a preference for collaborative decision-making as well as understanding the range of decision makers across time. DISCLOSURES: Daniel Suh, MS MPH, General Electric (Shareholder)Merck (Shareholder)Moderna (Shareholder)Smile Direct Club (Shareholder) Bruce Alexander, PharmD, Bruce Alexander Consulting (Independent Contractor) Andrew Pugely, MD, MBA, Globus Medical (Research Grant or Support)Medtronic (Consultant)United Healthcare (Consultant) Marin Schweizer, PhD, 3M (Grant/Research Support)PDI (Grant/Research Support)
format Online
Article
Text
id pubmed-8644068
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86440682021-12-06 92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship Dukes, Kimberly Walhof, Julia Sekar, Poorani Nair, Rajeshwari Suzuki, Hiroyuki Suh, Daniel Sherlock, Stacey Hockett Alexander, Bruce Richardson, Kelly Beck, Brice Reisinger, Heather Schacht Pugely, Andrew Puig-Asensio, Mireia Schweizer, Marin Open Forum Infect Dis Poster Abstracts BACKGROUND: Patients who develop prosthetic joint infections (PJI) may be prescribed chronic antibiotic suppression (CAS) ( > 6 months of antibiotics) after initial antibiotic treatment for the PJI. Patients at low risk of recurrent infection may be good targets for antibiotic stewardship. De-implementation of CAS could potentially reduce the emergence of antibiotic resistant organisms and decrease antibiotic-associated adverse events. Our ongoing study aims to characterize clinical decision-making processes about CAS prescribing and identify points for antibiotic stewardship interventions to stop CAS prescribing for patients who will not benefit. METHODS: We conducted semi-structured interviews with 33 physicians and nurses at 8 Veterans Affairs hospitals, chosen for variation in hospital size, complexity, region, and CAS prescribing. Interviewees included orthopedic surgeons, infectious disease (ID) physicians, hospital epidemiologists, nurses, nurse managers, and primary care physicians (PCPs). We conducted inductive, consensus-based thematic analysis on interview transcripts, using the program MAXQDA. RESULTS: Participants reported a complex decision-making process that included a range of collaborative approaches with other clinicians and patients. Their risk-benefit calculation for CAS usually included the type of revision surgery performed, the evidence base, the organism, and patient factors. Surgeons and ID physicians, the primary CAS prescribers, collaborated variably and sometimes consulted pharmacists or antibiotic stewards. Participants emphasized the importance of clinician autonomy and buy-in to order to effect practice change based on evidence, rather than top-down policies. They identified other significant time points that occurred before or after the CAS prescribing decision (initial PJI treatment decisions, follow-up appointments) and identified other decision makers about CAS maintenance (e.g., patients, PCPs). (See Figure 1). Figure 1. Decision Points Relevant to Prescribing or Maintenance of Chronic Antibiotic Suppression after PJI. PJI, prosthetic joint infection; ID, Infectious Diseases physician; PCP, primary care physician; IV, intravenous [Image: see text] CONCLUSION: Interventions to optimize CAS prescribing should incorporate clinician concerns about prescriber autonomy and a preference for collaborative decision-making as well as understanding the range of decision makers across time. DISCLOSURES: Daniel Suh, MS MPH, General Electric (Shareholder)Merck (Shareholder)Moderna (Shareholder)Smile Direct Club (Shareholder) Bruce Alexander, PharmD, Bruce Alexander Consulting (Independent Contractor) Andrew Pugely, MD, MBA, Globus Medical (Research Grant or Support)Medtronic (Consultant)United Healthcare (Consultant) Marin Schweizer, PhD, 3M (Grant/Research Support)PDI (Grant/Research Support) Oxford University Press 2021-12-04 /pmc/articles/PMC8644068/ http://dx.doi.org/10.1093/ofid/ofab466.294 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Dukes, Kimberly
Walhof, Julia
Sekar, Poorani
Nair, Rajeshwari
Suzuki, Hiroyuki
Suh, Daniel
Sherlock, Stacey Hockett
Alexander, Bruce
Richardson, Kelly
Beck, Brice
Reisinger, Heather Schacht
Pugely, Andrew
Puig-Asensio, Mireia
Schweizer, Marin
92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship
title 92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship
title_full 92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship
title_fullStr 92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship
title_full_unstemmed 92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship
title_short 92. Clinical Decision-Making about Chronic Antibiotic Suppression after Prosthetic Joint Infection Treatment: Qualitative Insights for Antibiotic Stewardship
title_sort 92. clinical decision-making about chronic antibiotic suppression after prosthetic joint infection treatment: qualitative insights for antibiotic stewardship
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644068/
http://dx.doi.org/10.1093/ofid/ofab466.294
work_keys_str_mv AT dukeskimberly 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT walhofjulia 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT sekarpoorani 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT nairrajeshwari 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT suzukihiroyuki 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT suhdaniel 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT sherlockstaceyhockett 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT alexanderbruce 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT richardsonkelly 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT beckbrice 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT reisingerheatherschacht 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT pugelyandrew 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT puigasensiomireia 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship
AT schweizermarin 92clinicaldecisionmakingaboutchronicantibioticsuppressionafterprostheticjointinfectiontreatmentqualitativeinsightsforantibioticstewardship